A screenshot from a webpage for "Exalgo® Hydromorphone HCI Extended-Release Tablets (CII)". The title of the page is "How many concomitant medications are your hydrocodone patients taking? Exalgo has reduced potential for certain drug-drug interactions. Unlike hydrocodone Exalgo is not metabolized through the CYP450 pathway." Below the title there are several bullet points about common drug class interactions and the consequences of drug-drug interactions. On the left side of the page there is an illustration of the liver which is a red color.
Beneath the illustration and bullet points there is an orange banner that reads "Key Takeaways: HCP - Reduced potential for drug-drug interactions; Patient - Undiminished efficacy". The bottom of the page includes references and the Exalgo logo.
Description
Type 
Category
-
Date
2013
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
